Business Description
Founded in 2019 and based in South San Francisco, Lycia Therapeutics is a biotech company with a novel approach to treating autoimmune, inflammatory, and allergic conditions. Rather than blocking harmful proteins, Lycia's proprietary LYTAC platform is built to eliminate them entirely by guiding the body's own cellular machinery to break them down. The company's pipeline includes candidates targeting IgE, a key driver of allergic reactions such as food allergy, as well as autoantibodies responsible for Graves' disease.
